Image pharmaphorum Editor Patients 2021 in review: Building the framework of a patient-centric ... Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action. R&D Drug development and working with specialised Rare Disease n... There are currently an estimated 300 million people living with one or more Rare Diseases across the world. News Frontiers Health 2021 Spotlight Digital Frontiers Health Digital Innovators: Aptar’s Sai Shankar Continuing his Frontiers Health Digital Innovator's series, pharmaphorum’s founder, Dr Paul Tunnah, speaks with president of Digital Health Sai Shankar. At Frontiers Health Load more results
Patients 2021 in review: Building the framework of a patient-centric ... Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action.
R&D Drug development and working with specialised Rare Disease n... There are currently an estimated 300 million people living with one or more Rare Diseases across the world.
Digital Frontiers Health Digital Innovators: Aptar’s Sai Shankar Continuing his Frontiers Health Digital Innovator's series, pharmaphorum’s founder, Dr Paul Tunnah, speaks with president of Digital Health Sai Shankar. At Frontiers Health
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.